Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F17%3A00067545" target="_blank" >RIV/65269705:_____/17:00067545 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/17:00098740

Result on the web

<a href="https://link.springer.com/article/10.1007%2Fs00277-017-3012-z" target="_blank" >https://link.springer.com/article/10.1007%2Fs00277-017-3012-z</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00277-017-3012-z" target="_blank" >10.1007/s00277-017-3012-z</a>

Result language

angličtina

Original language name

Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios

Original language description

With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY). Overall, 2-4% of dasatinib-treated patients had cardiovascular ischemic events. Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18). Most cardiovascular ischemic events occurred within 1 year of initiating dasatinib (pooled 69/96; DASISION 7/10; READY 16/18). Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Annals of Hematology

ISSN

0939-5555

e-ISSN

—

Volume of the periodical

96

Issue of the periodical within the volume

8

Country of publishing house

US - UNITED STATES

Number of pages

11

Pages from-to

1303-1313

UT code for WoS article

000404207100007

EID of the result in the Scopus database

—